🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 17 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 31/10/2000 | 90,69 | 96,38 | 89,00 | 93,11 | +2,88% | 8,13% | 7.193.400 |
| 30/10/2000 | 90,13 | 91,25 | 86,44 | 90,50 | -0,55% | 5,34% | 729.500 |
| 27/10/2000 | 94,25 | 96,00 | 83,75 | 91,00 | -4,15% | 13,00% | 886.100 |
| 26/10/2000 | 96,63 | 98,88 | 89,63 | 94,94 | -1,17% | 9,57% | 1.304.200 |
| 25/10/2000 | 89,00 | 97,13 | 87,00 | 96,06 | +3,36% | 11,38% | 1.333.000 |
| 24/10/2000 | 92,56 | 96,81 | 91,13 | 92,94 | +0,00% | 6,14% | 1.871.200 |
| 23/10/2000 | 81,00 | 93,63 | 80,50 | 92,94 | +16,54% | 16,20% | 1.811.700 |
| 20/10/2000 | 79,69 | 82,50 | 73,00 | 79,75 | -0,31% | 11,92% | 555.700 |
| 19/10/2000 | 81,88 | 83,38 | 77,56 | 80,00 | -0,47% | 7,10% | 773.100 |
| 18/10/2000 | 76,13 | 85,19 | 72,50 | 80,38 | +1,90% | 16,67% | 1.445.500 |
| 17/10/2000 | 74,63 | 79,88 | 74,56 | 78,88 | +6,59% | 7,12% | 1.219.200 |
| 16/10/2000 | 71,75 | 76,50 | 70,50 | 74,00 | +5,34% | 8,36% | 837.100 |
| 13/10/2000 | 65,81 | 70,25 | 63,00 | 70,25 | +5,05% | 11,02% | 1.169.400 |
| 12/10/2000 | 75,75 | 76,75 | 64,81 | 66,88 | -10,23% | 15,76% | 938.700 |
| 11/10/2000 | 71,75 | 75,13 | 69,38 | 74,50 | +3,03% | 8,01% | 919.500 |
| 10/10/2000 | 73,94 | 74,06 | 70,19 | 72,31 | -0,94% | 5,24% | 1.204.000 |
| 09/10/2000 | 65,50 | 73,44 | 64,00 | 73,00 | +10,40% | 14,41% | 1.136.800 |
| 06/10/2000 | 73,00 | 74,00 | 63,50 | 66,13 | -8,16% | 14,38% | 1.769.200 |
| 05/10/2000 | 78,25 | 80,56 | 69,50 | 72,00 | -6,42% | 14,14% | 935.500 |
| 04/10/2000 | 74,50 | 77,00 | 68,50 | 76,94 | +1,90% | 11,41% | 1.608.600 |
| 03/10/2000 | 82,88 | 85,63 | 75,38 | 75,50 | -7,93% | 12,37% | 938.700 |
| 02/10/2000 | 87,38 | 88,50 | 80,13 | 82,00 | -2,96% | 9,59% | 787.600 |
| 29/09/2000 | 91,69 | 94,81 | 84,50 | 84,50 | -9,38% | 11,25% | 1.096.300 |
| 28/09/2000 | 87,00 | 96,00 | 86,19 | 93,25 | +6,88% | 11,28% | 1.682.300 |
| 27/09/2000 | 85,31 | 88,00 | 85,13 | 87,25 | +3,41% | 3,37% | 893.100 |
| 26/09/2000 | 86,44 | 87,13 | 80,56 | 84,38 | -1,75% | 7,59% | 992.400 |
| 25/09/2000 | 89,38 | 90,00 | 85,13 | 85,88 | -3,31% | 5,45% | 1.307.600 |
| 22/09/2000 | 82,00 | 89,00 | 80,00 | 88,81 | +4,26% | 10,98% | 1.050.700 |
| 21/09/2000 | 84,06 | 86,00 | 84,00 | 85,19 | -1,30% | 2,38% | 701.500 |
| 20/09/2000 | 82,75 | 87,00 | 82,25 | 86,31 | +4,15% | 5,74% | 1.056.300 |